LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Immune Regulators Predict Severity of Plasmodium vivax Malaria

By LabMedica International staff writers
Posted on 17 Oct 2022
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)
Image: Ring-form trophozoites of Plasmodium vivax in a thin blood smear (Photo courtesy of Centers for Disease Control and Prevention)

Cytokines and chemokines are immune response molecules that display diverse functions, such as inflammation and immune regulation. In Plasmodium vivax infections, the uncontrolled production of these molecules is thought to contribute to pathogenesis and has been proposed as a possible predictor for disease complications.

Severe clinical manifestations described for P. vivax infections include neurological conditions, especially coma or successive seizures, and impaired consciousness; hematological conditions, in particular anemia, severe thrombocytopenia and hemoglobinuria; systemic symptoms, such as circulatory collapse, vital organ damage, including respiratory dysfunction and acute respiratory distress syndrome, acute kidney failure, splenic rupture, liver dysfunction, and jaundice.

Tropical Disease Specialists at the Universidad de Córdoba (Montería, Colombia) and their colleagues enrolled 156 participants in a study and classified them into three groups: 50 patients with severe malaria (SM), 56 non-severe malaria (NSM) and 50 healthy controls (HC), all from an endemic area. After confirming the diagnosis of P. vivax malaria by microscopy and molecular techniques; biochemical, hematological and parasitological parameters were determined.

Patients were classified as severe malaria if they met the criteria for any of the following complications: Hemoglobin concentration lower than 7 mg/dL was considered severe anemia, platelet concentration lower than 50.000 platelets/μL was considered severe thrombocytopenia, hypoglycemia (glucose < 60mg/dL), creatinine concentration higher than 1.3 mg/dL was considered indicative of renal dysfunction, Glutamic-pyruvic transaminase (GPT), Glutamic-oxaloacetic transaminase (GOT) concentration higher than 40 u/L was considered hepatic dysfunction.

IL-4, IL-2, CXCL10 (IP-10), IL-1β, TNF-α, CCL2 (MCP-1), IL-17A, IL-6, IL-10, IFN-γ, IL-12p70, CXCL8 (IL-8), and active TGF-β1 determination was performed in plasma, using the Human Essential Immune Response Panel kit (13-plex) (Biolegend, San Diego, CA, USA). Samples were run in duplicates in a FACSCalibur (Becton Dickinson, Franklin Lakes, NJ, USA).

The scientists reported that the levels of several cytokines and chemokines, CXCL10, IL-10, IL-6, IL-4, CCL2 and IFN-γ were found to be significantly higher in severe, compared to non-severe P. vivax malaria patients. Severe thrombocytopenia was positively correlated with IL-4, CXCL10, IL-6, IL-10 and IFN-γ levels; renal dysfunction was related to an increase in IL-2, IL-1β, IL-17A and IL-8, and hepatic impairment with CXCL10, MCP-1, IL-6 and IFN-γ. A Lasso regression model suggests that IL-4, IL-10, CCL2 and TGF-β might be developed as biomarkers for severity in P. vivax malaria.

The authors concluded that their study showed that there is a differential concentration of some cytokines and chemokines between patients with non-severe malaria and severe P. vivax malaria; and that there are associations between these molecules with manifestations that occur in severe malaria. Four molecules with potential to become biomarkers of severity were identified. The study was published on September 30, 2022 in the journal PLOS Neglected Tropical Diseases.

Related Links:
Universidad de Córdoba 
Biolegend 
Becton Dickinson 

Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
8-Channel Pipette
SAPPHIRE 20–300 µL
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more